Source link : https://www.newshealth.biz/health-news/fixed-duration-oral-doublet-for-fit-cll-wins-in-frontline-setting/
SAN DIEGO — A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with chemoimmunotherapy in fit patients with previously untreated chronic lymphocytic leukemia (CLL), the phase III AMPLIFY trial showed. The progression-free survival (PFS) rate at 3 years reached 76.5% with acalabrutinib (Calquence) plus venetoclax (Venclexta), as compared with 66.5% […]
Author : News Health
Publish date : 2024-12-09 17:39:37
Copyright for syndicated content belongs to the linked Source.